Innovotech Valuation
Is IOT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of IOT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate IOT's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IOT's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IOT?
Key metric: As IOT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is IOT's PS Ratio? | |
|---|---|
| PS Ratio | 4.8x |
| Sales | CA$1.49m |
| Market Cap | CA$7.15m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.7x |
| Enterprise Value/EBITDA | -16.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does IOT's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8x | ||
DOSE Rapid Dose Therapeutics | 25.8x | n/a | CA$34.7m |
TELI Telescope Innovations | 4.8x | n/a | CA$19.9m |
SZLS StageZero Life Sciences | 1.2x | n/a | CA$4.9m |
NDVA.H Indiva | 0.2x | n/a | CA$5.9m |
IOT Innovotech | 4.8x | n/a | CA$7.2m |
Price-To-Sales vs Peers: IOT is good value based on its Price-To-Sales Ratio (4.8x) compared to the peer average (8x).
Price to Sales Ratio vs Industry
How does IOT's PS Ratio compare vs other companies in the North American Life Sciences Industry?
| 10 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 10 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: IOT is expensive based on its Price-To-Sales Ratio (4.8x) compared to the North American Life Sciences industry average (3.3x).
Price to Sales Ratio vs Fair Ratio
What is IOT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 4.8x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate IOT's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Fennec Pharmaceuticals
US$127.3m
Operates as a biopharmaceutical company in the United States.
FRX
US$6.59
7D
8.0%
1Y
-43.4%
Medexus Pharmaceuticals
CA$53.0m
Operates as a pharmaceutical company in Canada and the United States.
MDP
CA$2.13
7D
4.9%
1Y
38.3%
Verano Holdings
CA$829.5m
Operates as a vertically integrated multi-state cannabis operator in the United States.
VRNO
CA$2.14
7D
-15.4%
1Y
-63.8%